Effervescent tablets help absorption better
Tirzepatide 15 mg, a dual agonist for glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, which has synergistic effects on appetite, energy intake, and fat mass, produced an average weight loss of 20.9% after 72 weeks
If your anticoagulation is managed by a cardiologist or hematologist, ensure they are also aware you are beginning GLP-1 therapy so they can advise on monitoring frequency
In addition to diabetes and obesity, GLP-1 drugs have been widely applied in clinical trials in various diseases, including fatty liver disease, cardiovascular disease, Alzheimer's disease, Parkinson's disease, and chronic kidney disease
Frei, M
Will switching to semaglutide mean I gain back weight